Kineta

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

Retrieved on: 
星期三, 五月 15, 2024
Patient, CPI, Pembrolizumab, VISTA, Workforce, NK, Clinical trial, Lung cancer, Bone marrow, AACR, Safety, Kineta, Cytokine release syndrome, CD27, AML, Cancer, Research, Chemokine, Biomarker, Infrared spectroscopy correlation table, Combination, Public expenditure, Failure, Acute myeloid leukemia, Pharmaceutical industry

“The Company announced additional clinical updates on the progress of the KVA12123 monotherapy and combination therapy results during the first quarter of 2024.

Key Points: 
  • “The Company announced additional clinical updates on the progress of the KVA12123 monotherapy and combination therapy results during the first quarter of 2024.
  • We continue to be pleased with these early clinical results as well as the accompanying biomarkers and immune cell data sets.
  • We look forward to sharing additional clinical updates in the second quarter and we will continue to explore strategic alternatives,” said Craig Philips, President of Kineta.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on: 
星期一, 四月 8, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Immunoglobulin G, Merck, Cancer, Pembrolizumab, Lung cancer, AACR, DLT, Clinical trial, Merck & Co., Kineta, NK, VISTA, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • Patients currently enrolled in the trial will be permitted to continue to participate.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Retrieved on: 
星期二, 三月 12, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Merck, Cancer, Pembrolizumab, Lung cancer, DLT, Merck & Co., Kineta, NK, Pharmaceutical industry

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as monotherapy and in combination with Merck’s anti-PD therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab. KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • We continue to be encouraged by the safety profile of KVA12123, supporting advancement to higher doses,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

Retrieved on: 
星期四, 二月 22, 2024
Poster, Cancer, Bone marrow, Acute myeloid leukemia, AML, AACR, Kineta

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.

Key Points: 
  • SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster.
  • The abstract will be published as a freely available supplement in an AACR journal on the first day of the symposium.
  • The poster will also be made available on the Kineta website following the presentation at the conference.

Kineta to Present at Upcoming Investor Conferences

Retrieved on: 
星期三, 二月 14, 2024
Kineta, Cancer

SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:

Key Points: 
  • SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the Company will be attending and presenting at the following upcoming investors conferences:
    Location: The New York Marriott Marquis, Uris room
    The Company will be available for one-on-one meetings during the conferences.
  • Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

Retrieved on: 
星期三, 二月 7, 2024
Kineta, VISTA, Patient, Cancer, Event

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024.

Key Points: 
  • SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat Series on February 13, 2024.
  • Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta and Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present an overview of recent clinical results of KVA12123, the company’s VISTA blocking immunotherapy in development for patients with advanced solid tumors.
  • The webcast presentation replay will be available for viewing on the Events & Presentations section of the Company's website.

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

Retrieved on: 
星期三, 十二月 13, 2023
Immunotherapy, Tumor microenvironment, Arm, Cancer, Kineta, Pembrolizumab, VISTA, Patient, Safety, Immunoglobulin G, Vaccine

SEATTLE, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the peer-reviewed publication in Frontiers in Immunology of preclinical data highlighting the potential of KVA12123 as a new immunotherapy against poorly immunogenic tumors. The publication titled “A Highly Potent Anti-VISTA Antibody KVA12123 - A New Immune Checkpoint Inhibitor and a Promising Therapy Against Poorly Immunogenic Tumors”, reports on the development of KVA12123.

Key Points: 
  • The publication titled “ A Highly Potent Anti-VISTA Antibody KVA12123 - A New Immune Checkpoint Inhibitor and a Promising Therapy Against Poorly Immunogenic Tumors ”, reports on the development of KVA12123.
  • “This scientific article summarizes the extensive characterization and selection of our clinical candidate KVA12123 that targets VISTA, a strong driver of immune suppression in the tumor microenvironment,” said Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • “The publication highlights the differentiating potency and safety characteristics of KVA12123 that guided its advancement into clinical development.
  • Additional clinical efficacy data in the monotherapy arm and initial combination data with pembrolizumab are anticipated in Q2 2024.

Kineta to Present at the Life Sciences Investor Forum December 14th

Retrieved on: 
星期二, 十二月 12, 2023
Cancer, Kineta

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present live at the Life Science Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023.

Key Points: 
  • SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, will present live at the Life Science Investor Forum, hosted by VirtualInvestorConferences.com, on December 14th, 2023.
  • Dr. Iadonato will engage in a “CEO Chat” session with John Vandermosten, Senior Biotechnology Analyst with Zacks Small-Cap Research.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

Retrieved on: 
星期四, 十一月 9, 2023
VISTA, Cancer, Kineta, Clinical trial, Patient, Pharmaceutical industry, Medical imaging

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the 5th Annual Macrophage-Directed Therapies Summit, to be held on November 13-15, 2023 in Boston, MA.

Key Points: 
  • SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the 5th Annual Macrophage-Directed Therapies Summit, to be held on November 13-15, 2023 in Boston, MA.
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present preclinical data on KVA12123, the company’s VISTA blocking immunotherapy, as well as an overview of the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
  • Title: VISTA-101 – A Phase 1/2 Clinical Trial of KVA12123, an Engineered IgG1 Targeting VISTA, Alone & in Combination With Pembrolizumab in Advanced Solid Tumors

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on: 
星期一, 十一月 6, 2023
VISTA, Patient, MCP1, Biomarker, Pembrolizumab, IL-6, SITC, Immunotherapy, Date, Immunoglobulin G, Clinical trial, NK, DLT, Cytokine release syndrome, Radiation, Annual general meeting, Date-time group, Tumor microenvironment, CXCL10, Safety, CRS, Cancer, Society, Pharmaceutical industry, Vaccine, Kineta

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.

Key Points: 
  • Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.
  • VISTA blocking immunotherapy KVA12123 has performed remarkably well in demonstrating excellent safety and tolerability in the clinic.
  • KVA12123 achieved a greater than 90% VISTA RO at the 30 mg dose indicating that KVA12123 may be approaching an optimal clinical dose.
  • Additional monotherapy safety and efficacy data and combination therapy clinical data are anticipated in the second quarter of 2024.